ChristophersonWM, LundinFEJr, MendezWM, ParkerJE. Cervical cancer control: A study of morbidity and mortality trends over a twenty-one-year period. Cancer, 1976; 38:1357–1366.
2.
SiegelR, NaishadhamD, JemalA. Cancer statistics, 2012. CA Cancer J Clin, 2012; 62:10–29.
3.
CopplesonLW, BrownB. Estimation of the screening error rate from the observed detection rates in repeated cercival cytology. Am J Obstet Gynecol, 1974; 119:953–958.
4.
DillnerJ, ReboljM, BirembautP, et al.Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint European cohort study. BMJ, 2008; 337:a1754.
5.
SchiffmanM, GlassAG, WentzensenN, et al.A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev, 2011; 20:1398–1409.
6.
ShermanME, LorinczAT, ScottDR, et al.Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: A 10-year cohort analysis. J Natl Cancer Inst, 2003; 95:46–52.
7.
CastlePE, RodriguezAC, BurkRD, et al.Short term persistence of human papillomavirus and risk of cervical precancer and cancer: Population based cohort study. BMJ, 2009; 339:b2569.
8.
KjaerSK, FrederiksenK, MunkC, IftnerT. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: Role of persistence. J Natl Cancer Inst, 2010; 102:1478–1488.
9.
PlummerM, SchiffmanM, CastlePE, Maucort-BoulchD, WheelerCM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis, 2007; 195:1582–1589.
10.
RodriguezAC, SchiffmanM, HerreroR, et al.Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst, 2008; 100:513–517.
11.
KorfageIJ, Essink-BotML, WestenbergSM, HelmerhorstT, HabbemaJDF, van BallegooijenM. How distressing is referral to colposcopy in cervical cancer screening?: A prospective quality of life study. Gynecol Oncol, 2014; 132:142–148.
12.
HeinonenA, GisslerM, RiskaA, PaavonenJ, TapperAM, JakobssonM. Loop electrosurgical excision procedure and the risk for preterm delivery. Obstet Gynecol, 2013; 121:1063–1068.
13.
JinG, LanlanZ, LiC, DanZ. Pregnancy outcome following loop electrosurgical excision procedure (LEEP) a systematic review and meta-analysis. Arch Gynecol Obstet, 2014; 289:85–99.
14.
ForsgrenC, LundholmC, JohanssonAL, CnattingiusS, ZetterstromJ, AltmanD. Vaginal hysterectomy and risk of pelvic organ prolapse and stress urinary incontinence surgery. Int Urogynecol J, 2012; 23:43–48.
15.
SaslowD, SolomonD, LawsonHW, et al.American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol, 2012; 137:516–542.
16.
MoyerVA. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med, 2012; 156:880–891, W312.
17.
AshokM, BerkowitzZ, HawkinsNA, TangkaF, SaraiyaM. Recency of Pap testing and future testing plans among women aged 18–64: Analysis of the 2007 Health Information National Trends Survey. J Womens Health (Larchmt), 2012; 21:705–712.
18.
BerkowitzZ, SaraiyaM, SawayaGF. Cervical cancer screening intervals, 2006 to 2009: Moving beyond annual testing. JAMA Intern Med, 2013; 173:922–924.
19.
TeohDG, MarriottAE, Isaksson VogelR, et al.Adherence to the 2012 national cervical cancer screening guidelines: A pilot study. Am J Obstet Gynecol, 2015; 212:62 e1–e9.
